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Poor peripheral blood stem cell (PBSC) mobilization predicts worse outcome for myeloma and lymphoma patients post
autologous stem cell transplant (ASCT). We hypothesize that PBSC harvest using plerixafor and G-CSF in poor mobilizers may
improve long-term outcome. We retrospectively analyzed the data on patients who had second PBSC mobilization using plerixafor
and G-CSF as a rescue. Nine lymphoma and 8 multiple myeloma (MM) patients received the drug. A control group of 25MM and
lymphoma patients who were good mobilizers with G-CSF only was used for comparison. Sixteen of the 17 poor mobilizers
proceeded to ASCT, and one MM patient had tandem transplants. Length of hospital stay, infection incidence, granulocyte
engraftment, and long-term hematopoietic recovery were not signiﬁcantly diﬀerent between the two groups. In conclusion, all
poor mobilizers were able to obtain adequate stem cells transplant dose and had similar transplant course and long-term outcome
to that of the control good mobilizers group.
1.Introduction
The use of peripheral blood stem cells (PBSCs) for au-
tologous and allogeneic transplantation has increased signif-
icantly in recent years. According to the Center for Interna-
tional Blood and Marrow Transplant Research (CIBMTR)
[1], more than 95% of autologous stem cell transplants
(ASCTs) and more than 70% of allogeneic stem cell
transplants are carried out with mobilized PBSC. The
advantages of using PBSC over bone marrow include shorter
engraftment time, less transfusions, shorter hospital stay,
convenience of stem collection, and rapid restoration of the
immune system [2–5].
The optimal PBSC mobilization strategy and the precise
identiﬁcation of patients at risk for poor mobilization need
to be further studied. Traditionally, mobilization of PBSC
for ASCT has been accomplished using cytokines alone
or in combination with chemotherapy [6–8]. However, a
signiﬁcant proportion of lymphoma and multiple myeloma
patients are poor mobilizers, that is, unable to achieve
the minimal target cell dose during their ﬁrst round of
mobilization and require a second round of mobilization
usingsalvageregimens.Studieshaveshownthattherearestill
signiﬁcant mobilization failures after these salvage regimens,
in addition to added toxicity, morbidity, and increased cost
[6, 7, 9, 10]. These patients face some serious consequences
such as inability to undergo potentially curative autologous
stem cell transplantation (ASCT), slow recovery of blood
counts after autografting, and higher rate of relapse [11–14].
Plerixafor (Mozobil), formerly known as AMD3100
(Genzyme, Cambridge, Mass, USA), is a CXCR4 antagonist
which has been recently approved for PBSC mobilization
in multiple myeloma (MM) and non-Hodgkin’s lymphoma
patients (NHL) undergoing ASCT. At our institution, we2 Advances in Hematology
participated in the pivotal phase III studies [15, 16]a sw e l l
as treated patients with plerixafor on the compassionate use
protocol. In this paper, we analyze the data on lymphoma
and MM patients who received the drug as a rescue during
a second cycle of mobilization using plerixafor and G-
CSF. Because of the known eﬀects of poor mobilization
on engraftment and long-term outcome after ASCT, we
hypothesized that better PBSC yields after mobilization with
plerixafor and G-CSF may improve the speed of recovery
of blood counts, reduce hospitalization days, and improve
the long-term outcomes. In order to test our hypothesis, we
retrospectively compared our poor mobilizers’ characteris-
tics and outcome with a similar group of patients who were
successfully mobilized with G-CSF only (good mobilizers)
and underwent ASCT during the same time period.
2. Patientsand Methods
2.1. Study Design and Patients. This is a retrospective insti-
tutional review board approved study involving MM and
lymphoma patients who underwent PBSC mobilization
for ASCT. Patients who received plerixafor were identiﬁed
through the records of our Clinical Trials Oﬃce. Total of
8MM and 9 lymphoma (8NHL and 1HD) patients received
plerixafor as a rescue mobilization in the Compassionate Use
Protocol (CUP). All patients signed informed consents at the
time of enrollment. Most likely, these patients were included
inthepublicationbyCalandraetal.[17].Asdescribedbefore
[17], entry into the protocol was limited to patients who
had previously failed to proceed to apheresis due to low
peripheral blood (PB) CD34+ cell counts (usually 10 cells
per mL or less) or based on apheresis yield were unlikely
to collect the minimum number for a single transplant,
usually 2 × 106 CD34+ cells per kg. In almost all cases this
assessment was made from the ﬁrst apheresis following the
mobilization. All our CUP patients had previously failed to
collect the minimal CD34+ cell dose (≥2.0 × 106 CD34+
cells/kg) for single transplant or double that for tandem
ASCTwithG-CSFalone.Inclusioncriteriaincludedageof18
to 70 years, failure of prior mobilization or collection, ability
to undergo transplant, WBC count >3.0 × 109 per liter,
ANC >1.5 × 109 per liter, PLT count >100 × 109 per liter,
serum creatinine ≤1.5mg/dL, liver function tests within 2x
upper limit of normal, Eastern Cooperative Oncology Group
performance status of 0 or 1, recovery from acute toxic
eﬀects of prior chemotherapy, left ventricle ejection fraction
>45%, Forced Expiratory Volume in the ﬁrst second >60%
of predicted or carbon monoxide diﬀusing capacity ≥45%
of predicted, and negative test for HIV infection. Exclusions
included brain metastases, acute infection, active infection
with hepatitis B or C, fever (>38◦C/100.4◦F), hypercalcemia
(>1mg/dL above the upper limit of normal), and pregnancy.
The control group included similar patients who were
goodPBSCmobilizersandwerepickedbasedontheirknown
disease diagnosis from a list of good mobilizers patients
provided by the Stem Cell Laboratory. Good mobilizers
were deﬁned as patients who had received G-CSF alone as
the mobilization regimen and achieved the minimal target
cell dose of ≥2 × 106 CD34+/kg for one transplant or ≥4
× 106 CD34+ cells/kg for two transplants (MM patients)
during their ﬁrst mobilization cycle. Total of 10MM and
15 lymphoma (14NHL and 1HD) patients were included
in the control group (referred to as good mobilizers). These
patients had already underwent ASCT during the same time
period like the study group and had similar eligibility criteria
for ASCT.
2.2. Administration of G-CSF and Plerixafor. The patients
were given G-CSF as per site preference, and so our patients
typically had two subcutaneous doses of G-CSF for a total of
10µg/kg, or ≥20µg/kg if they were deemed to be at high risk
for poor mobilization, for 4 days. At approximately 2200 on
the fourth day of treatment they were given a subcutaneous
dose of 0.24mg/kg plerixafor. On the morning of the ﬁfth
day, G-CSF was administered and apheresis (blood volumes
as per site preference) began at approximately 10h after
the plerixafor dose. Administration of G-CSF, apheresis
and administration of plerixafor were repeated daily until
the patient collected suﬃcient cells for transplantation
(minimum 2 × 106 CD34+ cells per kg). Treatment was
discontinued at the investigator’s discretion if the patient
failed to collect enough cells to warrant continuation. The
number of CD34+ cells collected during each apheresis
session was recorded.
2.3. Data Collected and Analyzed
Patients’ Characteristics. Include age, sex, diagnosis, stage
of disease, bone marrow involvement, number of prior
chemotherapy regimens, prior radiation therapy, prognostic
factors, time from diagnosis to PBSC mobilization, and
number of ASCT.
Stem Cell Mobilization Data. Include mobilization regimen,
G-CSF dose, number of apheresis days, white blood cell
(WBC) and platelets (PLT) counts on day 1 of apheresis,
CD34+ cell yield, CFU-GM counts in day 1 apheresis prod-
uct.
Transplant and Post-ASCT Data. Include CD34+ transplant
celldose,timetogranulocyteandPLTengraftment,lengthof
hospital stay, rate of infections, graft durability, progression-
free (PFS), and overall survival (OS). Engraftment of gran-
ulocytes was deﬁned as the ﬁrst of 3 consecutive days with
absolute granulocyte count (AGC) ≥0.5 × 109/L, while the
PLT engraftment was deﬁned as the ﬁrst day where the
PLT ≥20 × 109/L without transfusions. Graft durability was
deﬁned as maintenance of normal (acceptable) blood counts
at 3, 6, and 12 months after ASCT.
2.4. Statistical Analysis. The PFS and OS were estimated
by the Kaplan-Meier method. Both PFS and OS were
reported for MM and lymphoma poor mobilizer patients.
The statistical signiﬁcance of diﬀerences between the groupsAdvances in Hematology 3
Table 1: Patient characteristics: MM patients.
Poor
mobilizers
(n = 8)
Good
mobilizers
(n = 10)
Age, median (range), years 61 (48–67) 65.5 (30–73)
Sex
Male
Female
8
0
5
5
Disease stage
II
III
2
6
4
6
Disease status
CR/VGPR
PR
DP
2
6
0∗
3
7
0
B2M
Chromosome 13q/13 del
2.74 (1.68–5.84)
2
3.09 (1.3–5.18)
4
Median no. of prior treatment
regimens (range) 1 (1–3) 1 (1–3)
Prior lenalidomide (≥4c y c l e s ) 2 0
Prior RT 2 6
Median time from diagnosis
(range), days 206 (129–462) 204 (109–377)
Patients who had two transplants:
As salvage
As tandem
1
—
1
1
Posttransplant maintenance∗∗ 56
∗One patient was in PR at ﬁrst mobilization; however, he developed disease
progression by the time he went through the plerixafor mobilization. The
patient did not go through ASCT, and he was excluded from survival
analysis.
∗∗At 3 months of evaluation posttransplant, patients were oﬀered mainte-
nance therapy with thalidomide.
Note. The results show number of patients in each category unless indicated
otherwise.
was evaluated using the unpaired t-test and calculating two-
tailed P value. All statistical analysis was performed using the
GraphPad software Prism 4 (San Diego, Calif).
3. Results
3.1. Patient Characteristics. We studied total of 18MM and
24 lymphoma patients, including patients who received
plerixafor (poor mobilizers) and those who were successfully
mobilized without plerixafor (good mobilizers) who served
as controls for comparison (see Tables 1 and 2). Overall,
no major diﬀerences were noticed between the good and
poor mobilizers with either MM or lymphoma diagnosis.
It is important to point out that there was one Hodgkin’s
lymphoma patient in each group. The pretransplant condi-
tioning regimen for lymphoma patients included busulfan
0.75mg/kg PO or IV q 6h for 16 doses on days −8, −7,
−6, and −5 (total busulfan dose 12mg/kg) combined with
etoposide 10mg/kg IV on days −4, −3, and −2 (total
etoposide 30mg/kg) and cyclophosphamide 60mg/kg IV
on days −3a n d−2 (total cyclophosphamide 120mg/kg)
Table 2: Patient characteristics: lymphoma patients.
Poor
mobilizers
(n = 9)
Good
mobilizers
(n = 15)
Age, median (range), years 60 (36–65) 62 (21–75)
Sex,
Male
Female
5
4
9
6
Disease stage
II
III
IV
1
2
6
4
0
10
HD
NHL
1
8
1
14
Disease status
CR
PR
Relapse
6
2
1
11
4
0
Median no. prior treatment
regimens (range) 2 (1–3) 2 (1–3)
Prior RT 6∗ 5
Median time from diagnosis
(range), days
730
(376–1327)
1350
(72–6603)
BM involvement 2 0
∗One patient had radiation therapy (RT) during childhood.
Note. The results show number of patients in each category unless indicated
otherwise.
[11], and etoposide was omitted for patients who were
≥65 years old. The pre-transplant conditioning regimen for
MM patients was intravenous melphalan 200mg/m2 in most
patientsexceptfor3inthepoormobilizersgroupand2inthe
good mobilizers groupwhohadbusulfan/cyclophosphamide
± etoposide, as published before [18].
Our institutional policy is to avoid weekend apheresis,
and therefore chemotherapy + G-CSF mobilization is not
usually used. Our standard mobilization regimen involves
the use of G-CSF 5µg/kg BID. Patients with risk factors
for poor mobilization will usually receive higher dose of G-
CSF (10 or 16µg/kg BID). Indeed, and regardless of their
ﬁnalgroupdesignation,largenumberofMMpatients(37.5–
50%) and the majority of lymphoma patients (66.7–92.3%)
received the high G-CSF dose for their ﬁrst apheresis attempt
(Table 3). In general, patients who were poor mobilizers
and needed plerixafor for their second apheresis attempt
received the same G-CSF dose that was used for their ﬁrst
mobilization.Thusmanypoormobilizersendedupreceiving
high dose G-CSF with their plerixafor. The G-CSF dose was
not speciﬁed in the CUP, and therefore, the use of the high
G-CSF dose did not constitute a violation of the protocol.
Plerixafor was given at the recommended standard dose of
0.24mg/kgofbodyweightbysubcutaneousinjectionat2200
the day prior to each apheresis, that is, 10-11hr before the
start of apheresis.
3.2. Apheresis Outcomes. In order to study the eﬀects of
plerixafor on the apheresis and the quality of the stem4 Advances in Hematology
Table 3: The mobilization regimens used except when nonapplicable (N/A). Plerixafor dose was 0.24mg/kg for all patients given at 2200
the night before apheresis.
1st mobilization attempt 2nd mobilization attempt
G-CSF dose 5 BID µg/kg 10 BID µg/kg 16 BID µg/kg 5 BID µg/kg 10 BID µg/kg
MM, n
Poor mobilizers (n = 8)
Good mobilizers (n = 10)
5
4
3
5
0
1
5
N/A
3
N/A
Lymphoma, n
Poor mobilizers (n = 9)
Good mobilizers (n = 13)∗‡
3
1
6
12
0
0
2
N/A
7
N/A
∗One lymphoma control patient had chemotherapy + G-CSF 10µg/kg twice per day (BID).
‡In this group of 15 control lymphoma patients, mobilization regimen doses were not available for two patients.
Table 4: Summary of apheresis yields in the diﬀerent groups of patients.
CD34+ ×106/kg
Median (range) Median days of apheresis/cycle Median no. of CFU-GM
×105/kg∗
MM
Poor mobilizers (n = 8)
Good mobilizers (n = 10)
8.38 (2.4–25.1)
10.1 (6.4–12.3)
4 (2–5)
2 (2-3)
5.15 (0.45–9.3)
3.87 (0.0–13.9)†
Lymphoma
Poor Mobilizers (n = 9)
Good Mobilizers (n = 15)
3.85 (1.17–8.98)
5.56 (2.1–14.7)
3 (1–4)
2 (2–4)
2.01 (0.66–6.53)
2.01 (0.42–10.6)
∗T h e s en u m b e r sa r ef r o md a y1c o l l e c t i o n .
†One patient had 0 CFU-GM in one CFU assay.
cell product, we compared the study group to the control
group of good mobilizers using the number of CD34+ cells
collected, number of days of apheresis and the yield of CFU-
GM in the product of the ﬁrst apheresis, day for each patient
(see Table 4). As expected, the median CD34+ cells/kg was
slightly higher while the median number of apheresis days
was lower in the good mobilizers. However, the quality of
the collected stem cell product as measured by the number
of CFU-GM colonies was similar in both plerixafor + G-CSF
and G-CSF mobilized groups.
One myeloma patient in the plerixafor-mobilized
patients with manual diﬀerential count on day 1 had 21%
blasts and young cells in peripheral blood and 12% in
the apheresis product. This MM patient from the poor
mobilizers group relapsed with circulating plasma cells
shortly after the apheresis, and ﬂow cytometry analysis
conﬁrmed the presence of myeloma cells in his stem cell
product. The patient did not undergo ASCT and died from
his disease. In retrospect, the patient was already in relapse at
the time of his 2nd mobilization and apheresis.
We further analyzed the 13 patients (4MM and 9
lymphoma patients) who were truly poor mobilizers and
failed to collect ≥2 × 106 CD34+ cells/kg during the
ﬁrst mobilization with G-CSF only, thus excluding the
myelomapatientswhoweredeﬁnedaspoormobilizersbased
on their failure to collect ≥4 × 106 CD34+ cells/kg for
two transplants. We compared the 1st and 2nd stem cell
mobilizations (Table 5). The results show that during the
2nd mobilization with plerixafor and G-CSF, higher WBC
(P = 0.0003) was achieved on 1st day of apheresis. In
addition, the amount of CD34+ cells/kg was signiﬁcantly
higher during the 2nd mobilization (P = 0.025). These
results conﬁrm the eﬀectiveness of adding plerixafor to G-
CSF. Indeed, with the combination of products from ﬁrst
and second mobilization cycles, all patients had adequate
CD34+ cells dose for one or two ASCTs, although some
of them achieved only the minimal doses required for
single ASCT (2 × 106 CD34+/kg). The median infused
transplant CD34+ cell dose/kg for each group was as follows:
MM poor mobilizers 2.96 × 106 (range, 2.81–6.56 × 106);
MM good mobilizers 6.3 × 106 (range, 4.61–8.9 × 106);
lymphoma poor mobilizers 4.69 × 106 (range, 1.91–6.9 ×
106); lymphoma good mobilizers 6.64 × 106 (range, 5.02–
16.7 × 106).
3.3. Short- and Long-Term Hematologic Recovery. In order
to evaluate the quality of the plerixafor mobilized stem
cell products, we compared the study group to the good
mobilizers group for diﬀerent parameters such as length of
hospital stay, infections during hospital stay, engraftment
of granulocytes and platelets, and one-year hematopoietic
recovery as reﬂected by normal (acceptable) blood counts.
Table 6 shows the hospital course and the time to engraft-
ment were comparable between the good mobilizers and the
poor mobilizers. Although in the lymphoma poor mobilizers
group the median time to PLT engraftment (>20 × 109/L)
was 8 days longer than that of the good mobilizers; however,
this diﬀerence did not reach a statistical signiﬁcance.
The eﬀect of stem cell mobilization on normalization of
PBcounts,WBC,hemoglobin(Hgb)andhematocrit(HCT),
and PLTs, for both groups and diseases, was recorded.
Again, at 12 months after ASCT, there was no signiﬁcantAdvances in Hematology 5
Table 5: Comparison of laboratory and clinical data of truly poor mobilizers (deﬁned as not achieving ≥2 × 106 CD34+ cells/kg with ﬁrst
mobilization) during their 1st and 2nd mobilizations.
1st mobilization (G-CSF alone) 2nd mobilization (G-CSF + Plerixafor)
Median number of apheresis days (range) 3 (2–5) 2 (1–5)
Median CD34+ ×106/kg collected (range) 0.77 (0.24–1.98) 2.89 (0.72–22.5)∗
Median WBC on 1st day of apheresis, ×103/mm3 (range) 30.6 (5–59.6) 52.8 (21.2–94.6)∗
Median PLT count on 1st day of apheresis, ×103/mm3 (range) 114 (39–365) 132 (44–265)
†The number of poor mobilizers was 13, 4 multiple myeloma (MM) and 9 lymphoma patients. One MM patient died before transplant, and two patients had
tandem transplants. Median transplant cell dose for these patients was 3.68 × 106 CD34+/kg (range, 1.92–5.01).
∗Signiﬁcantly diﬀerent with P ≤ 0.025.
Table 6: Hospitalization course and engraftment: comparison between poor and good mobilizers.
Median hospital
stay (range)
Patients with proven infections
during hospital stay, n ∗
Median days to AGC ≥
500/mm3 (range)
Median days to PLT >20 ×
103/mm3 (range)
MM
Poor mobilizers (n = 8)
Good mobilizers (n = 10)
19 (15–25)
17 (16–24)
4
5
14 (12–15)
12 (10–15)
13 (11–46)
12.5 (10–20)
Lymphoma
Poor mobilizers (n = 9)
Good mobilizers (n = 15)
22 (19–52)
22 (18–30)
2
6
12 (11–33)
12.5 (10–21)∗∗
24 (17–58)
16 (11–240)∗∗∗
∗Infections include bacteremias, pneumonia, clostridium diﬃcile colitis, neutropenic colitis, and fungal infection.
∗∗One patient died during engraftment.
∗∗∗In addition to the patient who died during engraftment, one patient never reached platelet recovery until death.
NOTE: no signiﬁcant statistical diﬀerences in any of the above categories between poor mobilizers and control good mobilizers.
diﬀerence between those who received plerixafor + G-CSF
in the poor mobilizers group and those who received only
G-CSF mobilization in the good mobilizers group. At 12
months after ASCT, the median values for WBC, Hgb, and
PLTs were calculated for both poor and good mobilizers:
for MM patients, median WBC 4.2 × 109/L (range, 2.8–
6.1 × 109)a n d5 . 1× 109/L (range, 3.6–9.0 × 109), median
Hgb 12.8gr/dL (range, 10.8–15.4) and 12.3gr/dL (range
10.3–14.1), and median PLTs 149 × 109/L (range, 96–266
× 109) and 192 × 109/L (range, 150–297 × 109), for poor
and good mobilizers, respectively; for lymphoma patients,
median WBC 5.1 × 109/L (range, 2.2–11.8 × 109/L) and 5.3
× 109/L (range, 2.7–9.7 × 109/L), median Hgb 11.6 gr/dL
(range, 8.2–14.6) and 13.4 gr/dL (range, 7.1–15.5), and PLTs
125 × 109/L (range, 37–304 × 109) and 214 × 109/L (range,
25–337 × 109), for poor and good mobilizers, respectively.
Statistical analysis to detect signiﬁcant diﬀerences between
the two groups within the lymphoma and myeloma patient
populations was performed using the nonparametric Stu-
dent’s t-test. No signiﬁcant diﬀerences were detected with
the two-tailed P value being ≥0.266. There were similar
proportions of lymphoma patients in both groups (22.3
versus 23.08%, poor versus good mobilizers, resp.) with at
least one abnormal count, most likely reﬂecting the longer
course of pre-ASCT chemotherapy that they usually receive
in comparison to myeloma patients.
3.4. Long-Term Survival Outcomes. We assessed the eﬀects
on relapse and survival of better mobilization with the use
plerixafor. The Kaplan-Meier analysis for PFS and OS in the
MM and lymphoma poor mobilizer patients is shown in
Figure 1. Due to the retrospective nature of the study and the
small number of patients, we refrained from performing a
comparison to the control group.
In MM, the median followup for the poor mobilizers was
29 months (range, 10–45) and for the good mobilizers was
48.5months(range,11–58).Forpoormobilizers,themedian
PFSandOSwere22.5and40months,respectively.Therewas
one relapse in each group during the ﬁrst year after ASCT at
7.5 and 8 months.
In lymphoma patients, the median followup was 24
months(range,2–54)forthepoor mobilizersand28months
(range,0.6–55) forthe good mobilizer controlgroup. For the
poor mobilizers, the median PFS and OS were 17 and 24
months, respectively. There were 3 relapses within the ﬁrst
year, between 3–9 months after ASCT in the poor mobilizers
group, and 3 relapses in the good mobilizers group between
4–7 months after ASCT.
4. Discussion
The addition of plerixafor to G-CSF as ﬁrst line regimen
for peripheral blood stem cell (PBSC) mobilization has been
shown to be safe and eﬀective in two phase III placebo-
controlled randomized studies in MM and NHL patients
undergoing ASCT [15, 16]a sw e l la si nm u l t i p l ep h a s eI I
and retrospective studies in hard-to-mobilize patients [7, 14,
17, 19–21]. Plerixafor has been oﬀered to patients who failed
priormobilizationattemptsonacompassionateuseprotocol
(CUP) by Genzyme. The European compassionate use data
has been recently published [19]. Total of 56 patients from
15 centers in Spain and the UK were analyzed. The results6 Advances in Hematology
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Figure 1: The Kaplan-Meier curves for PFS (solid line) and OS (broken line) for MM patients (a) and lymphoma patients (b). The data
shown is only for the poor mobilizer patients.
showed that 75% of patients collected ≥2 × 106 CD34+/kg
and that 63% underwent transplant. All patients engrafted
neutrophils and PLTs. Followup was up to 6 months during
which 3 patients died from disease progression (2) or viral
pneumonitis (1). Five patients failed to mobilize adequately
with plerixafor and G-CSF and were not able to proceed to
ASCT. Two other publications from the CUP study showed
success rates for plerixafor plus G-CSF of 66–85% [17, 20,
21].
In our study, all patients except one relapsed MM patient
were able to undergo ASCT including two MM patients
whounderwenttandemtransplants.Theexplanationforthat
could be due to the fact that in many of our patients, the G-
CSF dose given with plerixafor was double the standard dose
of 10µg/kg/day. The reason for the use of such high dose of
G-CSFupfront,especiallyinmostofthelymphomapatients,
is most likely related to individual preferences by the treating
physiciansaswellastheuseofhigherG-CSFdosesinpatients
with known risks for poor mobilization. We have previously
reported poor PBSC mobilization to be as high as 52% in
lymphoma patients [10].
In this study, we used good mobilizers group in order
to compare the quality and long-term outcomes of PBSC
mobilization using plerixafor plus G-CSF versus G-CSF
alone. Several quality measures were compared including
median number of CD34+ cells/kg collected, median num-
ber of CFU-GM/kg, median hospital stay, incidence of
infections, time to engraftment of granulocytes and platelets,
and evidence of tumor mobilization by peripheral smear.
There were no signiﬁcant diﬀerences between the study
group and the control group in any of these measures. As
expected and according to published studies, time to platelet
recovery (≥20 × 109/L) was slower in the poor mobilizers
lymphoma patients (24 days) in comparison to the good
mobilizers group (16 days), but this was not statistically
signiﬁcant. Overall, all patients engrafted as expected and
there were no cases of primary or secondary graft failures up
to 12 months after the transplant. There were no treatment-
related deaths in the plerixafor-mobilized patients, while
two patients in the good mobilizers group died early from
transplant complications.
In this study, one myeloma patient who was remobilized
using plerixafor while he was already in relapse, developed
full blown relapse shortly after the stem collection and died
fromplasmacellleukemia.Thus,cautionshouldbeexercised
in the use of such powerful mobilizing combination of
plerixafor and G-CSF in relapsing MM patients. Examining
the PFS curves for the myeloma poor mobilizer group,
there was no early relapses to suggest possible myeloma
mobilization and reinfusion of myeloma contaminated stem
cell products. On the other hand, there were early relapses
in the plerixafor-mobilized lymphoma patients, but that
may be reﬂective of the known higher risk for relapse in
poor mobilizer lymphoma patients rather than reinfusion of
lymphoma contaminated stem cell products.
In the truly poor mobilizers patients (failed to achieve
≥2 × 106 CD34+ cells/kg in ﬁrst mobilization cycle) who
received plerixafor for their second mobilization, we have
seensigniﬁcantincreasesintheWBCcountsonthe1stdayof
apheresis in comparison to those seen in the ﬁrst mobiliza-
tion cycle. These patients also had one less day of apheresis
with signiﬁcant increase in the median CD34+ cells/kg
collected. These ﬁndings strongly support the published
data that show plerixafor to be a very eﬀective and well-
tolerated agent [14–17, 19–28]. Furthermore, the success
rate of plerixafor plus G-CSF appears superior to those
described previously with other alternative mobilization
protocols [6, 7, 9, 29, 30]. Prior treatment with lenalidomide
has been reported to increase the risk of poor mobilization
signiﬁcantly in MM patients [31, 32]. In our poor mobilizers
group, two MM patients had prior lenalidomide (≥4 cycles)
and were successfully mobilized using plerixafor for their
second mobilization cycle. The eﬀectiveness of plerixafor in
MM patients previously treated with lenalidomide has been
recently reported by Micallef et al. [33].
We and others have reported that poor mobilizer
lymphoma and MM patients had worse PFS and OS in
comparison to the good mobilizers [11–14]. Therefore, itAdvances in Hematology 7
is logical to use these end points to measure the impact of
plerixafor plus G-CSF mobilization. If more stem cells are
mobilized with the use of plerixafor in poor mobilizers that
resultinbetterandfasterrecoveryofhematopoiesis,thenitis
possiblethattheoverallsurvivalofthissubsetofpatientsmay
improve. Unfortunately, our current study is not designed to
provide such information because of the retrospective nature
and small number of patients. In this paper, we provide the
PFSandOSforthepoormobilizergrouponly.Futurestudies
should be designed to determine if there is indeed a positive
eﬀect of plerixafor on PFS and OS of lymphoma and MM
patients undergoing ASCT.
5. Conclusions
Our results conﬁrm the eﬀectiveness of plerixafor in mobi-
lizing and harvesting PBSC from lymphoma and myeloma
patients who failed G-CSF mobilization and therefore allow-
ing more patients to undergo ASCT. In addition, our study
also show comparable long-term engraftment and hospital
course for these poor mobilized patients in comparison to
control good mobilized group.
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